Phil Tennant, Chief Commercial Officer of Precigen Inc., sold 79,166 shares of the company’s common stock on August 25, 2026, at $7.50 per share for a total of $593,745. The transaction was executed under a pre-arranged 10b5-1 trading plan.
The disposal occurred as Precigen’s stock traded near its 52-week high of $7.55, following an 83% gain over the prior 12 months. InvestingPro’s analysis estimated the stock’s fair value at $7.33 at the time of the sale.
Separately, Tennant received 5,208 shares on August 23, 2026, from the settlement of restricted stock units granted on June 26, 2025. A portion of these units vested on the settlement date. To cover income tax obligations related to the RSU settlement, Precigen withheld 2,585 shares valued at $7.20 each, totaling $18,612.
On the same day, Tennant exercised options to purchase 79,166 shares at an exercise price of $1.61 per share. These options, which began vesting at 25% on July 22, 2025, will continue vesting in equal monthly installments over the next three years. The total value of shares acquired through option exercises and RSU settlements amounted to $127,457.
Precigen reported stronger-than-expected second-quarter 2026 financial results, posting earnings of $0.05 per share against an anticipated loss of $0.01 per share. Revenue reached $54.98 million, exceeding the forecast of $27.83 million, while net income totaled $20.1 million. The company cited strong demand for PAPZIMEOS, its approved therapy for adult recurrent respiratory papillomatosis.
